Where do we stand with radioimmunotherapy for acute myeloid leukemia?

Walter, Roland B.

doi:10.1080/14712598.2022.2060735

Cited by 7 publications

(4 citation statements)

References 75 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One potential approach is to incorporate agents (e.g. venetoclax or radioimmune conjugates) into the conditioning regimen that have synergistic effects with chemotherapy without increasing the level of non‐haematologic toxicity 44,45 …”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Early blast clearance during sequential conditioning prior to allogeneic stem cell transplantation in patients with acute myeloid leukaemia

Ronnacker,

Urbahn,

Reicherts

et al. 2024

Br J Haematol

View full text Add to dashboard Cite

SummaryFor patients with relapsed or refractory AML, sequential conditioning prior to allogeneic stem cell transplantation (alloSCT) is an established and potentially curative treatment option. Early response to treatment during conditioning indicates chemotherapy‐responsive disease and may have prognostic value. We retrospectively evaluated blast clearance on day 5 after melphalan, administered 11 days prior to alloSCT as part of a sequential conditioning in 176 patients with active AML. Overall survival (OS) was 52% (95% confidence interval [CI] 45%–60%), and relapse‐free survival (RFS) was 47% (95% CI 40%–55%) at 3 years. Patients who achieved early blast clearance did not show a significant improvement in OS and RFS (OS, hazard ratio [HR] HR 0.75, p 0.19; RFS, HR 0.71, p 0.09, respectively), but had a significantly lower non‐relapse mortality rate (HR 0.46, p 0.017). HLA‐mismatched donor, older age, adverse genetic risk and higher comorbidity scores were associated with inferior survival outcomes. A high initial blast count was only associated with inferior prognosis in patients receiving chemotherapy‐only compared to total body irradiation containing conditioning therapy. These results indicate that for patients transplanted with active AML, sensitivity to chemotherapy might be of less importance, compared to other disease‐ and transplant‐related factors.

show abstract

Section: Discussionmentioning

confidence: 99%

“…venetoclax or radioimmune conjugates) into the conditioning regimen that have synergistic effects with chemotherapy without increasing the level of nonhaematologic toxicity. 44,45 AU T HOR C ON T R I BU T ION S J.R., M.-A.U., L.K. and P.B.…”

Section: F I G U R Ementioning

confidence: 99%

Early blast clearance during sequential conditioning prior to allogeneic stem cell transplantation in patients with acute myeloid leukaemia

Ronnacker,

Urbahn,

Reicherts

et al. 2024

Br J Haematol

View full text Add to dashboard Cite

show abstract

“…RITs are in development by both academic and commercial sponsors. An anti-CD45 mAb, 131 I-apamistamab, is in Phase 3 clinical trials for acute myeloid leukemia ( 122 ) and an anti-PSMA mAb, 177 Lu-rosopatamab, is in Phase 3 clinical studies for metastatic castrate-resistant prostate cancer ( 123 ). However, the direction of radiotherapy seems to be towards smaller molecules such as peptides and small molecule drugs, as seen with the approvals of Lutetium Lu 177 Dotatate and 177Lu-PSMA-617 ( 124 , 125 ).…”

Section: Different Mab-based Formatsmentioning

confidence: 99%

Regulatory considerations in the design, development and quality of monoclonal antibodies and related products for the diagnosis and treatment of cancer

Shapiro

2024

Front. Oncol.

View full text Add to dashboard Cite

Over 160 therapeutic and in vivo diagnostic monoclonal antibodies have been approved by the US FDA since the first monoclonal antibody, muromonab, was approved in 1986. Approximately 42% of these approvals were for the treatment or in vivo diagnosis of oncology indications, although some products are no longer marketed. This review will look at the history of monoclonal antibody development and approvals, discuss current antibody-based modalities, regulatory considerations for engineering approaches, critical quality attributes for different modalities, immunogenicity of mAbs across oncology products, and the future directions for development of therapeutic and diagnostic monoclonal antibody-based products.

show abstract

“…Radiotherapy is the treatment of malignant tumors with radionuclide alpha, beta, gamma radiation and X-ray, electron and proton beams produced by various X-ray therapy machines or accelerators. Walter (2022) Radiation inevitably exposes normal cells to ionizing radiation, so there is a risk that cancer may develop again during treatment. Bodet-Milin et al (2016) .…”

Section: Introductionmentioning

confidence: 99%

Application of iron oxide nanoparticles in the diagnosis and treatment of leukemia

Wang

Yang²,

Zheng³

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

Leukemia is a malignancy initiated by uncontrolled proliferation of hematopoietic stem cell from the B and T lineages, resulting in destruction of hematopoietic system. The conventional leukemia treatments induce severe toxic and a long series of unwanted side-effects which are caused by lack of specificity of anti-leukemic drugs. Recently, nanotechnology have shown tremendous application and clinical impact with respect to diagnosis and treatment of leukemia. According to considerable researches in the context of finding new nanotechnological platform, iron oxide nanoparticles have been gained increasing attention for the leukemia patients use. In this review, a short introduction of leukemia is described followed by the evaluation of the current approaches of iron oxide nanoparticles applied in the leukemia detection and treatment. The enormous advantages of iron oxide nanoparticles for leukemia have been discussed, which consist of the detection of magnetic resonance imaging (MRI) as efficient contrast agents, magnetic biosensors and targeted delivery of anti-leukemia drugs by coating different targeting moieties. In addition, this paper will briefly describe the application of iron oxide nanoparticles in the combined treatment of leukemia. Finally, the shortcomings of the current applications of iron-based nanoparticles in leukemia diagnosis and treatment will be discussed in particular.

show abstract

Where do we stand with radioimmunotherapy for acute myeloid leukemia?

Cited by 7 publications

References 75 publications

Early blast clearance during sequential conditioning prior to allogeneic stem cell transplantation in patients with acute myeloid leukaemia

Early blast clearance during sequential conditioning prior to allogeneic stem cell transplantation in patients with acute myeloid leukaemia

Regulatory considerations in the design, development and quality of monoclonal antibodies and related products for the diagnosis and treatment of cancer

Application of iron oxide nanoparticles in the diagnosis and treatment of leukemia

Contact Info

Product

Resources

About